Myeloom geassocieerde studies

Planned studies

Naam EMN39
Titel A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant Conditions
Fase Fase 3
Therapie Linvoseltamab vs SOC
Doelstellingen Efficacy
Populatie Transplant ineligible NDMM
Eligibility Eligibility criteria in protocol
Status Not yet open
Informatie clinicaltrials.gov/study/ NCT06932562
Deelnemers EMC, Rotterdam
Naam QUINTESSENTIAL-2
Titel A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma
Fase Fase 3
Therapie BMS-986393 Versus Standard Regimens
Doelstellingen Efficacy (PFS)
Populatie RRMM: Prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible)
Eligibility Eligibility criteria in protocol
Status Not yet open
Informatie clinicaltrials.gov/study/NCT06615479
Deelnemers UMCG, Groningen; UMCU, Utrecht; UMCN, Nijmegen; MUMC, Maastricht, UAMC, Amsterdam

Open studies

Naam NCT05652335
Titel Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Fase Fase 1
Therapie JNJ-79635322, a Trispecific Antibody
Doelstellingen Safety and RP2D, part 1; dose escalation, part 2 dose expansion
Populatie RRMM and previously treated AL amyloidosis , as described in the protocol
Eligibility Eligibility criteria in protocol
Status Open
Informatie clinicaltrials.gov/study/NCT05652335
Deelnemers UMCU, Utrecht; UMCG, Groningen; AUMC, Amsterdam
Naam SUCCESSOR-2
Titel A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Fase Fase 3
Therapie MeziKD vs Kd
Doelstellingen Efficacy (PFS)
Populatie Prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible)
Eligibility Eligibility criteria in protocol
Status Open
Informatie clinicaltrials.gov/study/ NCT05552976
Deelnemers MST, Twente; Amphia ZH, Breda
Naam NCT05201781
Titel A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Fase Fase 4, Data collection
Doelstellingen Collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Populatie Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
Eligibility Eligibility criteria in protocol
Status Open
Informatie clinicaltrials.gov/study/NCT05201781
Deelnemers UAMC, Amsterdam; UMCG, Groningen
Naam MagnetisMM-32
Titel A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide
Fase Fase 3
Therapie Elranatamab vs SOC (Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd))
Doelstellingen Efficacy (oa PFS)
Populatie 1 to 4 PL,  including anti-CD38 antibody and prior lenalidomide.
Eligibility Eligibility criteria in protocol
Status Open
Informatie clinicaltrials.gov/study/NCT06152575
Deelnemers MUMC, Maasstricht; ASZ, Dordrecht; EMC, Rotterdam
Naam ITUMM
Titel Telemonitoring Among Patients With Multiple Myeloma
Fase Fase 3
Therapie Telemonitoring vs SOC monitoring
Doelstellingen  

Impact on Correct Drug Use, Complications and Quality of Life
using telemonitoring (MM e-coach) vs standard MM care. Impact on Correct Drug Use, Complications and Quality of Life

Populatie Multiple Myeloma
Eligibility Eligibility criteria in protocol
Status Open
Informatie clinicaltrials.gov/study/NCT05964270
Deelnemers Zwolle, Overijssel, Netherlands

 

Naam iMMagine-3
Titel A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)
Fase Fase 3
Therapie Anitocabtagene Autoleucel vs SoC
Doelstellingen Efficacy (PFS)
Populatie Relapsed/ Refractory Multiple Myeloma
Eligibility Eligibility criteria in protocol
Status Open
Informatie clinicaltrials.gov/study/NCT06413498
Deelnemers UMCG, Groningen
Naam EMN40
Titel A Phase 2 Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis
Fase Fase 2
Therapie Teclistamab monotherapy, duration 6 months
Doelstellingen Hematological CR rate after 3 cycles
Populatie Relapsed patients with AL amyloidosis
Eligibility Previously treated with an alkylating agent and/or a proteasome inhibitor and dexamethasone and/or daratumumab and/or IMID. Measurable hematological disease (dFLC > 20), eGFR > 20 ml/min
Status Open 15 June 2025
Informatie EMN40 - European Myeloma Network
Deelnemers UMC Utrecht
Naam EMN28/Cartitude-6/EM-agine
Titel A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
Fase Fase 3
Therapie Dara-VRD/HDM/ASCT vs DaraVRD/CAR-T
Doelstellingen Efficacy (PFS) en safety
Populatie NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Informatie EMN28 - European Myeloma Network
Deelnemers EMC, Amsterdam UMC, UMCU, UMCG, Radboud UMC
Naam EMN33/ TAURUS
Titel Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants with Previously Untreated Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS
Fase Fase 2
Therapie Dara-VRD, HDM/ASCT. Gebuik makend van bloodbased MRD
Doelstellingen Efficacy (PFS) en safety
Populatie NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Informatie EMN 33 - European Myeloma Network
Deelnemers Many hospitals in the Netherlands, inform at a centre near you
Naam EMN30/ MAJESTEC-4
Titel Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – The Majestec-4 study
Fase Fase 3, onderhoud
Therapie Teclistamab/ Lenalidomide vs. Teclistamab vs. Lenalidomide
Doelstellingen Efficacy (PFS) en safety
Populatie NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Informatie EMN30 - European Myeloma Network
Deelnemers EMC, Amsterdam UMC, UMCG, ASZ, and other centres, inform at a centre near you
Naam MAGNETISMM-6
Titel Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone In Transplant-ineligible Participants With Newly-diagnosed Multiple Myeloma
Fase Fase 3
Therapie Elranatamab + daratumumab + lenalidomide (EDR) versus Daratumumab + lenalidomide + dexamethasone (DRd)
Doelstellingen Efficacy (PFS) en safety
Populatie NDMM TIE patients
Eligibility NDMM transplant ineligible
Status Open
Informatie https://clinicaltrials.gov/study/NCT05623020
Deelnemers VieCuri, ASZ
Naam Excaliber-maintenance
Titel A Randomized, 2-arm, Phase 3 Study Of Elranatamab (Pf-06863135) Versus Lenalidomide In Patients With Newly Diagnosed Multiple Myeloma After Undergoing Autologous Stem-cell Transplantation
Fase Fase 3, onderhoud
Therapie Iber vs len onderhoud na autoPSCT
Doelstellingen Efficacy (PFS) en safety
Populatie NDMM TE patients, onderhoud
Eligibility NDMM transplant eligible
Status Open
Informatie https://clinicaltrials.gov/study/NCT05317416
Deelnemers ASZ Dordrecht 
Naam MAJESTEC-7
Titel A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Fase Fase 3
Therapie Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR)
Doelstellingen Efficacy (PFS) en safety
Populatie NDMM TE patients
Eligibility NDMM transplant eligible
Status Open
Informatie https://clinicaltrials.gov/study/NCT05552222
Deelnemers Amsterdam UMC; Antonius; Reinier de Graaf ZH Delft;

Gelre ZH, Apeldoorn; St Antonius ZH, Nieuwegein; Zuiderland Medisch centrum, Sittard-Geleen

Naam MagnestisMM-7
Titel A Randomized, 2-Arm, Phase 3 Study of Elranatamab (PF-06863135) Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
Fase Fase 3
Therapie Elranatamab Versus Lenalidomide maintenance
Doelstellingen Safety and Efficacy (part 1, safety lead-in, part 2 randomized)
Populatie

Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation.
MRD measured by NGS (central lab)

Eligibility Eligibility criteria in protocol
Status Open in HAGAZH
Informatie https://clinicaltrials.gov/ct2/show/NCT05317416
Deelnemers

Isala ZH, Zwolle; MUMC, Maastricht

Naam MagnestisMM-5
Titel

A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Fase Phase 3
Therapie  Elranatamab Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone
Doelstellingen Safety and Efficacy (part 1, safety lead-in, part 2 randomized)
Populatie

Only open for part 2
Part 2:  >1 PL, niet dara-refractair

Eligibility Eligibility criteria in protocol
Status Not open yet
Referentie https://clinicaltrials.gov/ct2/show/NCT05020236
Deelnemers

MUMC / ErasmusMC

 

Naam MonumenTAL-6
Titel A phase 3 randomized study comparing talquetamab in combination with pomalidomide (Tal-P), talquetamab in combination with teclistamab (Tal-Tec) and investigator’s choice of either elotuzumab, pomalidomide and dexamethasone (EPd) or pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory myeloma who have received 1 to4 prior lines of therapy including an anti-CD38 antibody and lenalidomide
Fase Fase 3
Therapie Talquetamab+pomalidomide versus Talquetamab+teclistamab versus elotuzumab+pomalidomide (EPd) of pomalidomide+bortezomib (PVd)
Doelstellingen Efficacy (PFS) en safety
Populatie RRMM
Eligibility RRMM, 1-4 eerdere lijnen (behandeld met lenalidomide en antiCD38 antistof)
Status Open
Referentie https://clinicaltrials.gov/study/NCT06208150
Deelnemers

Flevoziekenhuis, Almere; HagaZH, Den Haag; Catherina ZH, Eindhoven; AntoniusZH, Nieuwegein; IsalaZH, Zwolle

Closed studies

EMN29
Majestec-3
Majestec-9
EXCALIBER
Trimm-2 studie
Majestec-1
Monumental-1
Monumental-2
Monumental-3
Celgene CC-220-MM-001
ICON
LAVA
Gen3014-01
CA058-002
EMN34/ ERASMM
79635322MMY1001
EMN22
LYNX

Up